GlassScriptPhysician profile
Joshua W Mccarthy
NPI 1578827408
$4,632.79
in general payments reported to CMS, 2019-2025
39 companies · $925 in 2025
The $925 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,234 · 2020: $945 · 2021: $948 · 2022: $13.41 · 2023: $17.62 · 2024: $550 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,492.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $634.75 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $418.77 | 2020-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $379.20 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $347.14 | 2019-2025 | Airsupra |
| Abbvie INC. | $306.20 | 2021-2025 | |
| Pfizer INC. | $303.88 | 2019-2025 | |
| Astellas Pharma US INC | $271.50 | 2019-2021 | |
| Lilly USA, LLC | $224.65 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.75 | 2019-2025 | Jardiance, Synjardy |
| Merz North America, INC. | $175.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.76 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $110.21 | 2024-2025 | Caplyta |
| Antares Pharma, INC. | $90.74 | 2019-2024 | Xyosted |
| Merck Sharp & Dohme LLC | $81.83 | 2019-2021 | |
| Boston Scientific Corporation | $74.80 | 2024-2025 | General - Pain Management |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Mccarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.